August 14, 2023 11:26 AM EDTUpdated 11:36 AM

After patient death, FDA slaps clinical hold on early-stage AML trial studying 2seventy bio asset

Paul Schloesser

Associate Editor

A Seattle Children’s Hospital-led trial studying 2seventy bio’s CD33-targeted CAR-T cell therapy, SC-DARIC33, in acute myeloid leukemia has been put on clinical hold by the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After patient death, FDA slaps clinical hold on early-stage AML trial studying 2seventy bio asset

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Jazz wins approval for bispecific in biliary tract cancer

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

Are programs with compounded GLP-1s safe for your population?

Af­ter pa­tient death, FDA slaps clin­i­cal hold on ear­ly-stage AML tri­al study­ing 2sev­en­ty bio as­set

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

After patient death, FDA slaps clinical hold on early-stage AML trial studying 2seventy bio asset

Jazz wins approval for bispecific in biliary tract cancer

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

Are programs with compounded GLP-1s safe for your population?